New Delhi: On 13th May, Pharmaceutical firm Suven Life Sciences said it has been granted one patent each by Europe and Hong Kong for a drug used in the treatment of neurodegenerative diseases.
Neurodegenerative diseases include Alzheimer's, Schizophrenia and Parkinson's.
In a BSE filing, the company said it has been granted "one product patent from Europe and one product patent from Hong Kong corresponding to the new chemical entities for the treatment of disorders associated with neurodegenerative diseases".
Suven Life Sciences CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medial need with huge market potential globally."
With these new patents, Suven has a total of 16 granted patents from Europe and 17 from Hong Kong.
"These patents are exclusive intellectual property of Suven... Products out of these inventions may be out-licensed at various phases of clinical development like at phase-1 and phase-2," Suven Life Sciences said.
Meanwhile, Suven Life Sciences was trading 3.37 percent up at Rs 291.65 on BSE.
